Introduction
Prostate-specific antigen (PSA) levels have become a surrogate end point for monitoring the effectiveness of definitive treatments for clinically localized prostate cancer. Following radical prostatectomy, the PSA must become undetectable to indicate potential cure. 1 Because most laboratories use a PSA assay that has a sensitivity of 0.2 ng/ml, this value is used in most instances to define potential cure. 2 In a small percentage of cases a PSA nadir below 0.5 ng/ml is considered an acceptable definition of potential cure. This level is occasionally used because the residual cancer detection limit of the assays widely used to assess postprostatectomy biochemical recurrence has been shown to be 0.4 ng/ml. 3 This may be due in part to residual noncancerous prostatic tissue left in place at the time of radical prostatectomy. Therefore, surgeons generally use any PSA increase above nadir values of 0.2 ng/ml or 0.5 ng/ml to define biochemical failure, which is most likely due to the growth of cancer cells that were left behind at the time of radical surgery. 4 The definition of biochemical failure following radiation therapy is somewhat more controversial. The American Society of Therapeutic Radiology and Oncology (ASTRO) committee currently does not use a PSA nadir to indicate potential cure, but instead defines biochemical failure as three consecutive rises in PSA during unspecified intervals of 3 -6 months. 5 Alternatively, Critz and colleagues 6 have recently reported that PSA levels can flare secondary to the development of a chronic inflammatory state following radiation therapy. In their study, the mean rise in the PSA level was 0.4 ng/ml. Because of this phenomenon, some radiation therapists use a single rise in PSA level greater than 0.5 ng/ml to indicate biochemical failure. 6 Because three definitions of biochemical failure are currently being used -(1) a PSA nadir of greater than 0.5 ng/ml; (2) any PSA rise greater than 0.5 ng/ml; and (3) three consecutive increases in PSA levels at unspecified 3 -6-month intervals -we wanted to know whether this could potentially affect how failure rates are reported. To find out, we calculated the biochemical failure rates using these three definitions in a contemporary group of patients with low-grade, localized prostate cancer who received standard definitive treatment.
Materials and methods
This study comprised a retrospective review of 315 men who presented to our institution between January 1996 and December 1998 with low-grade, clinically localized prostate cancer and who were eligible for definitive treatment of their disease. Low-grade disease was defined as a Gleason score of 6 or less. Patients with a Gleason score greater than or equal to 7 prostate cancer or a PSA value greater than 10 ng/ml were excluded from this study because of the increased likelihood of undetected advanced disease. These parameters were chosen to ensure the comparison of these applied definitions across a cohort of men with biologically similar cancers. Patients were excluded from the study if they received neoadjuvant or adjuvant hormone therapy, which may have contributed to biased reporting of potential biochemical failures unrelated to the applied definition.
The 315 men underwent one of three definitive treatments for localized prostate cancer that are offered at out institution: three-dimensional, conformal, external-beam radiation therapy (n ¼ 99), I-125 brachytherapy (n ¼ 109), or anatomic radical retropubic prostatectomy (n ¼ 107). The choice of treatment was based on patient and physician discussion and preference. The median radiation dose in the brachytherapy series was 14400 cGy. In the three-dimensional, conformal radiation therapy group, the median radiation dose was 7000 cGy, which was delivered using a 4-and 6-field technique. Each patient's PSA level was assessed before treatment and at 6-month intervals afterwards using the Hybritech 1 (Beckman Coulter) system. Biochemical failure was determined following treatment using three definitions: (1) a PSA nadir of greater than 0.5 ng/ml; (2) any single rise in PSA level from nadir by an increment of greater than 0.5 ng/ml; and (3) three consecutive rises in PSA level (ASTRO definition).
The PSA levels of patients in each treatment group were compared at 12, 24 and 36 months using a 2-tailed McNemar test for proportion comparisons as this data was not normally distributed. All statistical computations were performed with SAS version 8.1 (SAS Institute Cary, NC, USA) software. The data conformed to the assumptions of this statistical test. Differences in the failure rates were considered significant when P < 0.05.
Results
Patient demographics and disease characteristics for each of the three treatment groups are listed in Table 1 . All patients completed the therapy. The median follow-up for the entire series was 72 months (range 12 -72 months). Table 2 and Figure 1 show the calculated biochemical failure rates for the brachytherapy group. At all three follow-up points (12, 24 and 36 months), the rates differed depending on the definition that was used. Interestingly, at 36 months follow-up, there were no cases of biochemical failure when definition 3 (the ASTRO definition of three consecutive rises in PSA level) was applied, yet 57% of patients had PSA levels that met the requirements of biochemical failure when definitions 1 (a PSA nadir of > 0.5 ng/ml) and 2 (any rise in PSA level greater than 0.5 ng/ml) were applied. Differences between the reported failure rates were statistically significant at 12, 24 and 36 months of follow-up (Table 2) . Table 3 and Figure 2 show the biochemical failure rates in the three-dimensional, conformal, external-beam radiation therapy group. Again, the biochemical failure rates differed depending on the definition used. The differences were especially striking at 12 months followup when 68% of patients had potentially reportable cases of biochemical failure when definition 1 was applied vs 5% when definitions 2 and 3 were used. As with the brachytherapy group, statistically significant differences between the failure rates were evident at 12, 24 and 36 months follow-up (Table 3) . Table 4 lists the biochemical failure rates for the radical prostatectomy group. No PSA level in this group met the requirements of biochemical failure for any of the three definitions.
Discussion
This study's main finding is the definition of biochemical failure can significantly influence the reporting of failure rates following brachytherapy and three-dimensional, conformal, external-beam radiation therapy for lowgrade, clinically localized prostate cancer. Because the PSA level has become an important tool for defining potential cure of prostate cancer and identifying cancer relapse, it is incumbent on the medical community to identify the PSA level that best indicates potential cure and above which disease recurrence is present. Currently, there is considerable confusion in the literature about what level(s) should be for any given definitive treatment for this disease. When radical surgery is performed, the PSA level reaches a nadir of < 0.2 ng/ml by 6 months following treatment. Of the cohort of men in this series who underwent radical retropubic prostatectomy (n ¼ 107), not one had a PSA level that met any of the three definitional requirements of biochemical failure. This is not surprising given the rapid decline of PSA levels to undetectable levels following radical surgery and the relatively short follow-up of this cohort.
Because PSA levels take a median of 27 months to reach nadir after of any type of definitive radiation therapy, the PSA level that defines potential cure and subsequent recurrence is less clear. 7 Recently, Critz et al 6 reported that PSA levels can increase secondary to the development of chronic inflammatory changes within the treatment bed 12 -18 months following combined, simultaneous radiation therapy with I-125 seeds and externalbeam radiation therapy. 6 This phenomenon occurred in nearly one-third of their patients and the mean rise in PSA due to this phenomenon in that series was 0.4 ng/ml. Thus, some radiation oncologists define biochemical failure (cancer recurrence) as any rise from the PSA nadir of greater than 0.5 ng/ml to adjust for this benign phenomenon as well as for inherent laboratory variability.
Currently, the Radiation Therapy Oncology Group defines biochemical failure using definition 3 -the ASTRO definition of three consecutive rises in PSA level determined at unspecified intervals of 3 -6 months. 5 Unfortunately, this definition is quite ambiguous, and it can potentially delay the diagnosis of cancer recurrence by 18 months. This definition can also delay the potential reporting of biochemical failure. Thus, when this definition is used in research studies, it can bias the data and conclusions by an average of 12 -18 months.
Reports from the Memorial Sloan-Kettering Cancer Center and the Radiotherapy Clinics of Georgia have correlated the nadir PSA level at 12 and 18 months following radiation therapy with long-term biochemical failure. 8 -10 Zelefsky et al 8 reported that when the PSA level failed to nadir at less 1.0 ng/ml by 12 months after treatment, only 27% of his patients with prostate cancer were free of disease at 3 y. Critz et al, 9 who studied 943 men with this disease, suggested that a PSA nadir of 0.2 ng/ml or less -the same definition for potential cure used in the surgical literature -must be achieved to indicate the cure of prostate cancer by radiotherapy. In some of their patients, the PSA level failed to increase past this cut-off point; at 5-plus years follow-up, 92% of these men had not experienced biochemical recurrence. When the PSA nadir was 0.2 -0.5 ng/ml, 56% of these men remained free of biochemical recurrence, and when the nadir PSA was > 0.5 ng/ml, only 12% of these radiotherapy patients remained free of biochemical recurrence.
In our series, the applied definition of biochemical failure factored significantly in the potential reporting of treatment failure in the brachytherapy and external beam, conformal, three-dimensional radiotherapy groups. The differences were apparent at all three follow-up points (12, 24 and 36 months). We acknowledge the fact that this difference may be exaggerated at 12 months secondary to incomplete nadir in the radiation therapy groups. Yet at 24 months of follow-up, the biochemical failure rates still differed considerably from one another and some of these differences were statistically significant. Additionally, we recognize the length of follow-up for the entire cohort is short and longer follow-up may increase the number of identified biochemical recurrences. However, the variability in the reporting of these potential failures is still evident within this follow-up period. It appears from the literature that a PSA nadir of < 0.2 -0.5 ng/ml correlates well with potential cure of clinically localized, well-differentiated prostate cancer regardless of treatment modality.
Conclusions
While we acknowledge the small numbers of patients and limited follow-up in this study, we feel we have demonstrated that the applied definition of biochemical failure can dramatically influence the reporting of potential treatment results following either I-125 brachytherapy or three-dimensional, conformal, external-beam radiation therapy for low-grade, clinically localized prostate cancer. These findings underscore the need for a more universal definition of biochemical failure across multiple disciplines, especially if the efficacy of various treatment options is to be compared in the definitive treatment of localized prostate cancer. 
